A stabilized fabric composed of a mesh or a woven fabric is disclosed as are methods of their manufacture, the manufacture of medical devices made using a stabilized fibers and stabilized medical devices are all disclosed. Fabrics can be stabilized by several techniques including: using mechanical, chemical and/or energetic fasteners at warp and weft intersections in the weave; by using various weaving techniques and fibers. Meshes can be stabilized when properly dimensioned and arranged junctions and struts of the necessary properties are used. All of these stabilized fabrics can be made of synthetic polymer materials such as ultrahigh molecular weight PE or PP and expanded PTFE.

A vascular prosthesis (e.g., stent), and packaging and delivery system to selectively deliver a vascular prosthesis are described. In some embodiments, the vascular prosthesis utilizes a low porosity and high porosity section, and the packaging and delivery system allows the prosthesis to be delivered such that the position of the low porosity and high porosity sections of the prosthesis can vary.

A mesh element having a mesh gauge selected to control flow of materials therethrough. The mesh element is implantable into an anatomical structure upstream of a body passage or within a body passage to control flow of materials through the body passage. The mesh element may be coupled to a support structure to facilitate anchoring of the mesh element in place relative to the body passage. The support structure may have a lumen defined therethrough to allow flow of materials through the body passage, with the mesh element regulating the flow of materials into the lumen. The mesh element alternatively may be directly coupled to an anatomical structure upstream of a body passage to regulate or determine flow of materials through the body passage.

Modular endoprosthesis for at least partial replacement of a tubular bone, comprising, as module components, a stem for insertion into a bone cavity of the tubular bone, and an end piece comprising a support body with a neck part arranged on the medial aspect thereof. Said module components being able to be coupled to each other and released from each other along a longitudinal axis of the shaft. The end piece has at least two different surface configurations on its support body, namely a closed surface (6′) on a medial aspect, and a porous configuration of the surface on the opposite, lateral aspect. The latter permits and positions the adhesion of muscle tissue, specifically without suturing. The muscle trauma caused by suturing, and the peak loads that occur at the respective suture points, can thus be avoided by virtue of the invention, by means of the location-specific direct adhesion of the muscle. It is thus possible to achieve quicker and reliable mobilization of the patient, and this with a reduced risk of complications.

The present invention provides an artificial skin and a preparation method thereof. The present invention takes the xenogeneic acellular dermal matrix particles as main materials, and obtains the dermis layer by three-dimensional printing technologies, and then obtains the artificial skin by combining the epidermis layer with the dermis layer. The dermis layer of artificial skin in present invention has three-dimensional porous structure, which retains main components of natural dermal matrix in composition, and imitates distributed structure at fiber bundle diameter and pore size of natural dermal matrix in structure. This kind of novel biomimetic dermal scaffolds have obvious advantages in inducing migration and regeneration of skin cells, accelerating vascularization, promoting wound healing and improving healing quality. The dermis layer of artificial skin in present invention is obtained by three-dimensional printing technologies, which has precise and controllable structure, simple preparation method and high products qualification rate.

Embodiments herein relate to an implant for insertion into a patient. The implant comprises a plurality of unit cells arranged to form a three-dimensional lattice structure, the three-dimensional structure comprising a resting volume of the implant. The plurality of unit cells are arranged to form a porous network of the three-dimensional structure, and wherein the three-dimensional structure is a reversibly compressible three-dimensional structure, wherein a bulk porosity of the three-dimensional structure of the implant is at least 50%. Also disclosed is a method of tissue reconstruction or tissue augmentation. The method comprises implanting into the body of a subject an implant of the disclosure.

The present invention disclosed a method of producing a three-dimensional porous tissue in-growth structure. The method includes the steps of depositing a first layer of metal powder and scanning the first layer of metal powder with a laser beam to form a portion of a plurality of predetermined unit cells. Depositing at least one additional layer of metal powder onto a previous layer and repeating the step of scanning a laser beam for at least one of the additional layers in order to continuing forming the predetermined unit cells. The method further includes continuing the depositing and scanning steps to form a medical implant.

A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.

Glaucoma treatment systems are disclosed. In various example, the glaucoma treatment systems include a body and a fluid conduit configured to facilitate an evacuation of fluid, such as aqueous humor, from a fluid-filled body cavity, such as an anterior chamber of an eye. In some examples, the fluid conduit is soft and compliant, and the glaucoma treatment system includes one or more stiffening members coupled with the fluid conduit to temporarily stiffen the fluid conduit and help aid in the delivery of the glaucoma treatment device. In some examples, the stiffening members are removable from the fluid conduit after the glaucoma treatment system has been implanted.

An implantable medical device and methods for making and using the same are provided. In various embodiments, the device comprises a central hub structure in communication with at least one housing or pod capable of containing cells and therapeutic materials. Also provided are membrane structures and methods of forming the same, the membranes comprising a gradient of varying porosity for use with devices of the present disclosure, as well as other uses.